The earnings call presented a mixed picture. On the positive side, there is significant international expansion and promising changes in the Medicare fee schedule that could boost future demand. However, current financial performance shows declines in revenue, gross margin, and a net loss, compounded by challenges related to a proposed LCD affecting reimbursement. While there are positive strategic initiatives and growth opportunities, the financial downturn and reimbursement uncertainties create a balanced sentiment.

Company Guidance

During the Sensus Healthcare Second Quarter 2025 Financial Results Conference Call, several metrics and key developments were discussed. The company reported revenues of $7.3 million for Q2 2025, a decline from $9.2 million in Q2 2024, primarily due to fewer capital system sales. Gross profit for Q2 2025 was $2.9 million, with a gross margin of 39.7%, compared to 58.7% in the prior year. The net loss for the quarter was $1 million, or $0.06 per share, contrasting with a net income of $1.6 million or $0.10 per diluted share in Q2 2024. Adjusted EBITDA was negative $1.8 million, reflecting higher operating expenses and lower revenue. The company delivered 19 SRT systems in Q2, including 4 to China, and signed 5 new FDA contracts. Medicare’s proposed physician fee schedule, which could significantly increase reimbursement for SRT delivery codes, was also highlighted. Sensus remains optimistic about its long-term revenue trajectory and expects a resolution to the local coverage determination (LCD) challenge regarding ultrasound reimbursement, which has temporarily paused sales momentum. The company ended the quarter with $22.2 million in cash and no debt.

International Expansion

Sensus Healthcare shipped 19 SRT systems in Q2, with 4 sold to China, indicating growing international demand. Additionally, the company received MDSAP certification, enabling access to markets in Brazil, Canada, Japan, and Australia.

Partnerships and FDA Treatment Volume

Sensus signed 5 new FDA contracts and activated 4 sites in Q2, with FDA treatment volume increasing by 27% over Q1. The company also appointed Radiation Oncology Systems as a primary distribution partner for the hospital-based oncology segment.

Proposed Medicare Fee Schedule

A proposed Medicare physician fee schedule could significantly increase reimbursement for delivering SRT, potentially transforming the U.S. commercial strategy and increasing demand for the company's products.

Sensus Healthcare (SRTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SRTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	-0.08 / -	0.07	―	―	―
Aug 07, 2025	2025 (Q2)	0.03 / -0.06	0.1	-160.00% (-0.16)	―
May 15, 2025	2025 (Q1)	0.03 / -0.16	0.14	-214.29% (-0.30)	―
Feb 05, 2025	2024 (Q4)	0.12 / 0.09	0.26	-65.38% (-0.17)	―
Nov 14, 2024	2024 (Q3)	-0.01 / 0.07	-0.09	177.78% (+0.16)	―
Aug 08, 2024	2024 (Q2)	0.02 / 0.10	-0.02	600.00% (+0.12)	―
May 09, 2024	2024 (Q1)	-0.04 / 0.14	-0.12	216.67% (+0.26)	―
Feb 08, 2024	2023 (Q4)	0.14 / 0.26	0.17	52.94% (+0.09)	―
Nov 09, 2023	2023 (Q3)	-0.02 / -0.09	0.11	-181.82% (-0.20)	―
Aug 03, 2023	2023 (Q2)	-0.08 / -0.02	0.21	-109.52% (-0.23)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SRTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$5.35	$3.46	-35.33%
May 15, 2025	$4.66	$4.46	-4.29%
Feb 05, 2025	$8.99	$6.08	-32.37%
Nov 14, 2024	$7.29	$7.64	+4.80%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sensus Healthcare (SRTS) report earnings?

Sensus Healthcare (SRTS) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).

What is Sensus Healthcare (SRTS) earnings time?

Sensus Healthcare (SRTS) earnings time is at Nov 06, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SRTS EPS forecast?

SRTS EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing